| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Operating activities | ||||||||
Net loss | ||||||||
-46,859 | -39,247 | -32,784 | -29,294 | -26,736 | -23,846 | 0 | 0 | 0 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | ||||||||
197 | 174 | 147 | 125 | 109 | 105 | 0 | 0 | 0 |
Stock-based compensation | ||||||||
1,654 | 1,421 | 1,069 | 674 | 466 | 332 | 0 | 0 | 0 |
Gain (Loss) From Remeasurement Of Derivative Liability | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Non-cash interest expense | ||||||||
503 | 500 | 438 | 1,157 | 2,428 | 3,664 | 0 | 0 | 0 |
Non-cash research and development expense | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Other non-cash transactions | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Change in fair value warrant liability | ||||||||
- | - | - | - | - | -11 | 0 | 0 | 0 |
Change in fair value derivative liability | ||||||||
- | - | - | - | - | -676 | 0 | 0 | 0 |
Changes in operating assets and liabilities: | ||||||||
Other receivable | ||||||||
226 | 1,000 | 0 | 0 | 0 | - | - | - | - |
Prepaid expenses and other assets | ||||||||
11,465 | 1,954 | 807 | 3,151 | 1,354 | 1,017 | 0 | 0 | 0 |
Accounts payable | ||||||||
-135 | 802 | 665 | 2,695 | 1,433 | 1,337 | 0 | 0 | 0 |
Accrued expenses and other current liabilities | ||||||||
493 | -327 | 185 | 311 | 647 | 1,923 | 0 | 0 | 0 |
Deferred rent | ||||||||
- | - | - | - | - | 17 | 0 | 0 | 0 |
Net cash used in operating activities | ||||||||
-54,690 | -39,594 | -33,943 | -29,279 | -23,150 | -17,053 | 0 | 0 | 0 |
Investing activities | ||||||||
Purchases of property and equipment | ||||||||
1,434 | 960 | 912 | 520 | 197 | 119 | 0 | 0 | 0 |
Acquisition of intellectual property rights | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Net cash used in investing activities | ||||||||
-1,534 | -960 | -912 | -520 | -197 | -119 | 0 | 0 | 0 |
Financing activities | ||||||||
Proceeds from development derivative liability | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Payments of deferred stock offering costs | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Long-term borrowings, net | ||||||||
0 | - | 0 | 0 | 0 | - | - | - | - |
Proceeds from exercise of stock options | ||||||||
262 | 245 | 0 | 0 | 0 | - | - | - | - |
Repayments of long-term debt | ||||||||
0 | 938 | 0 | 0 | 0 | - | - | - | - |
Net cash provided by (used in) financing activities | ||||||||
63,751 | 53,528 | 0 | 0 | 0 | - | - | - | - |
Net decrease in cash and cash equivalents | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Net increase (decrease) in cash and cash equivalents | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Supplemental disclosure for cash flow | ||||||||
Cash paid for interest | ||||||||
724 | 576 | 456 | 361 | 319 | 260 | 0 | 0 | 0 |
Supplemental disclosure of cash flow information | ||||||||
Supplemental disclosure of non-cash investing and financing activities | ||||||||
Issuance of warrants in conjunction with development derivative liability | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Accrued interest on term loan refinanced to principal | ||||||||
0 | 308 | 0 | 0 | 0 | - | - | - | - |
Issuance of warrants in conjunction with debt | ||||||||
146 | 355 | 0 | 0 | 0 | - | - | - | - |
Debt refinanced with new term loan | ||||||||
0 | 6,563 | 0 | 0 | 0 | - | - | - | - |
Initial recognition of operating lease right-of-use assets and operating lease liabilities | ||||||||
0 | - | 0 | 0 | 0 | - | - | - | - |
Accretion of redeemable convertible preferred stock | ||||||||
- | - | - | - | - | 95 | 0 | 0 | 0 |
Deferred stock offering costs in accounts payable | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Purchases of property and equipment included in accounts payable and accrued expenses | ||||||||
1,843 | 823 | 0 | 0 | 0 | - | - | - | 0 |